Aurobindo Pharma's Lamotrigine ANDA Submission Receives AP Status
Aurobindo Pharma's ANDA078956 for Lamotrigine has received an Abbreviated Approval (AP) status from the FDA.
Regulatory Event
New Drug Application and Biologics License Application filings that initiate formal regulatory review.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.